Business Wire

Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes

KRYSTEXXA has demonstrated rapid reduction in the serum uric acid level for people with uncontrolled gout; however, as with any biologic, the immune system can sometimes react to the therapeutic ...
Business Wire

Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled ...
Nasdaq

Target Enrollment Reached in MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) Co-Prescribed with Methotrexate as an Immunomodulator to Enhance ...

-- Randomized controlled trial will add to results from prior open-label trial and in-practice case series -- DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the ...
Healthline

Recognizing and Treating Early Symptoms of Gout

The first signs of gout are usually pain, swelling, and redness in the affected joint. Gout often starts in your big toe, and symptoms tend to come on suddenly and at night. Gout is a painful form of ...
Nasdaq

Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease

-- MIRROR randomized controlled trial data to be presented during Kidney Week 2022 show consistent kidney function, eGFR levels, for people receiving KRYSTEXXA with methotrexate throughout the ...